Collaborating with a Multitude of Partners

Teva has built and sustains one of the largest generic research and development teams in the industry.
Collaborating with a Multitude of Partners

We play an important role in contributing to healthcare systems worldwide, and our stakeholders increasingly want us - and the industry - to be even more active. We participate in advancing a culture of medical and scientific excellence by collaborating with a multitude of partners, sharing knowledge and advancing capabilities with leading academic institutions, nonprofits, governments and corporations that demonstrate a meaningful commitment to advancing global health through R&D. We apply this process both to developed world and developing world needs.

For example, our Global Public Health Program, launched in 2012 under our R&D group, focuses on developing and manufacturing NTEs to provide solutions for public health needs in developing countries. We aim to expand sustainably and tackle challenges of access and affordability through our business, not philanthropy. In line with the United Nation’s Millennium Development Goals, we are currently creating new medical solutions in two critical public health domains: family planning and child mortality from diarrhea.

Progressing Clinical and Dementia Research

In 2014, we began to partner with the UK National Health Service and committed $20 million to clinical research in the UK and funded an additional $1 million of early stage research into dementia in an effort to find potential new treatment approaches. Making progress on neurodegenerative disease is urgently needed. According to the World Health Organization, the number of people living with dementia is set to reach 115 million in less than 40 years, and the global cost of managing this disease currently exceeds $604 billion a year.

Targeting Degenerative Brain Diseases

Israel is a world leader in neuroscience research, ranked fifth globally in neuroscience publications per capita. It is one of the most daunting and rewarding areas in medicine, and Teva is well-positioned to help advance global understanding of the causes and continue to modernize urgently needed therapies that will make many people’s lives better.

To capitalize on this concentration of expertise in research and in medicines, in 2012 Teva established the Israeli National Network of Excellence in Neuroscience (NNE) as a collaborative research community, helping to deliver research and research pathways that make a significant difference. The NNE has proven successful in engaging leading universities and teaching hospitals in Israel behind this cause.

As part of the NNE program, Teva is contributing $15 million over five years to fund top researchers and research students at 10 leading Israeli research institutes. The first cohort of more than 40 researchers is already making progress toward the treatment of diseases such as Alzheimer’s disease, MS, ALS, Huntington’s disease and Parkinson’s disease.

Investing in Research Centers

Last year, we expanded our research funding by partnering with Bar Ilan University. Our joint $8 million investment will establish two state of-the-art research centers in the north of Israel to advance understanding of autism and rare genetic diseases.

The Teva Center for Neuroscience Research will help the Faculty of Medicine in the Galilee establish a national registry of Israelis with autism spectrum disorders. Correlated to tissue samples, the registry will help researchers identify environmental factors and disturbed biological pathways and then develop targeted therapies. The Teva Center for Human Genetics, at the Western Galilee Hospital, Nahariya, will focus on research into the high frequency of genetic causes of death in the Galilee to develop new therapeutic approaches to reduce morbidity.

We hope to create brighter futures for those whose genetic makeup impedes on their overall health and well-being.